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ABSTRACT
Background: Despite tremendous progress in the control of the global tuberculosis (TB)
epidemic during the past decade, it is still a major health problem even today. The burden of TB
is particularly severe in sub-Sahara Africa where TB and HIV co-infection is common,
especially in those who are smear-negative. Such patients are twice more likely to die from TB
than their counterparts because of delayed diagnosis and treatment. This thesis focuses on the
evaluation of currently available new tests which have been developed to facilitate rapid
diagnosis and early treatment of TB.
Aims: The purpose of this thesis was to increase knowledge about the diagnostic accuracy,
cost-effectiveness and effect on treatment of TB of the new tests in smear-negative HIV-
positive patients in a context where resources are limited.
Methods: In study I, a systematic review was performed to summarize and compare the over-
all accuracy for smear-negative TB of the existing traditional TB tests (WHO 2007 TB
algorithm) and two new tests: Xpert MTB/Rif test (a molecular-based method) and Microscopic
Observation Drug Susceptibility test (a culture-based method). In study II, a cross-sectional
study was performed to collect primary laboratory data on the diagnostic accuracy for smear-
negative TB of Xpert MTB/Rif (GeneXpert), Microscopic Observation Drug Susceptibility test
(MODS) and Nitrate Reductase Assay (NRA) in HIV-positive patients. The results of the three
tests were compared with traditional solid Löwenstein-Jensen (L-J) TB culture and a new
conventional liquid (MGIT) TB culture method. In study III, we modelled the cost-
effectiveness of using MODS or GeneXpert-based algorithm for diagnosis of pulmonary TB in
HIV-positive patients. Finally, in study IV, we investigated how best to treat patients with
presumptive pulmonary TB who were both Smear and GeneXpert negative.
Results: From study I, we found that the sensitivity of the tests for smear-negative TB was
moderate (61-73%). The specificity was high for both GeneXpert (98%) and MODS (91%) but
moderate for the WHO 2007 TB algorithm (69%). From study II, we found that GeneXpert,
MODS and NRA had low sensitivity for smear-negative TB in HIV-positive patients (24-49%).
However, the specificity of all three tests was high (92-98%). From study III, we found that
utilizing a MODS-based algorithm for diagnosis of pulmonary TB in HIV-positive patients was
more cost-effective than utilizing a GeneXpert-based algorithm (US$ 34 versus US$ 71 per TB
patient diagnosed). From study IV, we found that a smear and GeneXpert-negative test result
had a high negative predictive value for TB. Thus, despite the low-moderate sensitivity of
GeneXpert for smear-negative TB, a majority of patients (88%) responded fully to antibiotic
treatment and empiric TB treatment was initiated in only a few (8%) of them.
Conclusions: GeneXpert, MODS and NRA are useful for diagnosis of TB in smear-negative
patients including those who are HIV-positive. The tests could be used to improve the existing
WHO 2007 TB algorithm. But since they have low-moderate sensitivity, additional evaluation
for TB is required in those who test negative using these new tests. The high specificity of
GeneXpert, MODS and NRA implies they are highly reliable to initiate TB treatment in those
with positive results. From an economic view point, utilizing a MODS-based algorithm for
diagnosis of TB in HIV patients is more cost-effective than a GeneXpert-based algorithm.
Therefore, where resources are limited, MODS could be used as an alternative to GeneXpert.
Using an antibiotic treatment trial in HIV patients who are both smear and GeneXpert negative
could be useful to reduce empiric TB treatment because of the high negative predicative value
for TB of the two combined tests.
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11 INTRODUCTION
1.1 MICROBIOLOGY OF MYCOBACTERIA
Mycobacteria are subdivided into three groups: The Mycobacterium tuberculosis
complex (MTC), Mycobacterium leprae and Non-tuberculosis mycobacteria
(NTM) [1]. In humans, disease from Tuberculosis (TB) is caused by
Mycobacteria from the MTC group within which, Mycobcaterium. tuberculosis
(MTB) is the principal agent. MTB can be distinguished from other agents within
the MTC group by its ability to reduce nitrate to nitrite [2].
Mycobacteria are non-motile and non-spore forming aerobic rods measuring 0.2-
0.6 x 1 -10 µm in size. Their envelope structure consists of mycolic acids of 60 to
90 carbons, with a high content (61-71%) of guanine and cytosine in their DNA
[3]. Species variations are characterized by variation in sugar substitutions in the
cell wall of the mycobacteria. Further, their cell wall is rich in lipids, making the
surface hydrophobic and resistant to many disinfectants, including common
antibiotics and common laboratory stains [1, 4]. However, once stained, they
cannot be decolorized with acid solutions, and are therefore acid-fast. Other
important wall components include the glycolipid trehalose dimycolate [5], which
is thought to induce cord-like growth of mycobacteria on artificial media and
lipoarabinomannan (LAM) a glycolipid which may play a role in virulence [6].
Compared to other bacteria which typically reproduce within minutes,
Mycobacteria grow extremely slowly with a generation time of 18-24 hours
because of their complex cell wall [4]. In addition, Mycobacteria are fastidious in
nature, requiring specially enriched media for growth and enhanced by the
presence of 5-10% CO2 in a limited temperature range of 35-37 oC [1, 4].
1.2 RE-EMERGENCE OF TB AND THE EARLY CONTROL STRATEGY
Tuberculosis (TB) disappeared from the global public health agenda in the 1960s
and 1970s because of improved socioeconomic conditions and the discovery of
TB medicines leading to its decline during this period [7]. However, with the
onset of the HIV pandemic in the 1980s, coupled with increases in drug
resistance, TB re-emerged in the early 1990s and was declared a ‘global health
emergency’ by the World Health Organization (WHO) in 1993 [8].
For nearly 25 years since 1990-2015, an estimated 7-9 million new TB patients
occurred annually. During this period, between 1.5-2 million individuals died
from TB annually, reaching a peak in 2004 [9]. In sub-Saharan Africa, due to the
HIV epidemic, the number of TB patients doubled or tripled in some countries.
TB became the leading cause of mortality in the region with HIV/AIDS as the
commonest underlying factor [10-12].
2In response to the alarming TB situation, the WHO launched the DOTS strategy.
The DOTS strategy aimed to use cure of the infectious cases as the best
prevention for TB transmission [13, 14]. The target was to detect at-least 70% of
those infectious cases and cure at-least 85% of them by the year 2000. The DOTS
strategy relied on smear-microscopy for TB detection and a standardized short
course regimen for TB treatment.
1.3 GLOBAL INITIATIVES FOR TB CONTROL
Reports on the DOTS strategy revealed suboptimal progress towards the set
targets [7, 10]. For example, a report of the DOTS strategy in 1998 showed that
only a handful of countries had achieved the set detection and treatment success
targets for TB [15]. In addition, there were persistent difficulties in TB diagnosis
coupled with high TB mortality rates. It is during this period, that the momentum
to set up new global initiatives for TB control picked up.
This momentum led to the creation of the STOP TB partnership and development
of the first Global plan to Stop TB 2000-2005 [16]. The first ‘Global plan to Stop
TB 2000-2005’ was intended to expand DOTS coverage, address HIV associated
TB and drug resistant TB, and to pursue innovative research for new TB
diagnostics, drugs and vaccines [17]. In parallel, the Global Fund was established
in 2002 to increase resources to fight AIDS, Tuberculosis and Malaria [18]. The
second ‘Global plan to stop TB 2006-2015’ set out the actions and funding
needed to accelerate progress in TB control [19]. The targets in the second plan
included reduction of the global TB prevalence and mortality by half relative to
the 1990 levels by 2015. The key strategies in the second plan for achieving the
set targets included scaling up existing interventions and the introduction of new
technologies, notably new TB diagnostics.
1.4 CURRENT GLOBAL TB BURDEN
Globally, TB mortality and TB prevalence have fallen by 45% and 41%
respectively since 1990 [20]. Despite the decline however, an estimated 9 million
people continue to develop TB and 1.5 million continue to die from the disease
annually (Figure 1). Furthermore, the current TB detection levels are suboptimal
because nearly three million of the incident cases are not diagnosed, keeping TB a
top cause of respiratory disease world-wide [21]
3Figure 1: Graphic of the current global TB burden [22]
The factors that influence the continued high global TB burden are several. They
classically include poverty, overcrowding and malnutrition. However, by far, HIV
remains the strongest risk factor for TB. In an individual with HIV, the risk of
developing TB is 20-30 times compared to an individual without HIV [23-25].
Of the estimated 9 million incident TB patients annually, 12% (1.1 of 9 million)
are infected with HIV [20]. Furthermore, nearly half a million of these incident
TB patients have multi-drug resistant TB (MDR-TB). Interestingly, despite the
rapid deterioration and high mortality in HIV patients infected with MDR-TB, the
association between MDR-TB and HIV infection is still unclear. One recent meta-
analysis found that HIV increased the risk for MDR-TB [26], while another meta-
analysis found no such association [27].
The highest burden of TB is in those aged 35-54 years which is the most
economically productive age group. Although TB mainly occurs in men, nearly
40% of patients (3.3 out of 9 million) are women and 6% (550,000 of 9 million)
are children aged less than 15 years [20].
Globally, only about 50% of new patients have a bacteriologically confirmed
diagnosis of pulmonary TB. A substantial proportion (37%) are treated for
pulmonary TB empirically while the rest (14%) are treated for extra-pulmonary
TB. This pattern is evident in all regions of the world [20].
4World-wide, the biggest burden of TB (80% of incident cases and 95% of deaths)
occurs in twenty-two low or middle income countries [20]. In 2013, most of the
incident TB patients were from Asia (56%) with India, China, Pakistan and
Indonesia standing out, and from Africa (29%) with Nigeria and South Africa
standing out (Figure 2).
Regionally, the burden of TB continues to be highest in sub-Saharan Africa [15,
20]. In 2013, the incidence of TB in sub-Saharan Africa was twice (281 compared
to 126 per 100, 000 population) the incidence at global level. In addition, TB
mortality in sub-Saharan Africa was nearly three times (42 compared to 16 per
100,000 population) the mortality at global level [20].
Within sub-Saharan Africa, the southern region is the most affected with some
countries such as South Africa and Swaziland having TB incidence rates of 860
and 1382 per 100,000 population respectively (7-10 times the global rate). The
region also has the highest levels of mortality from TB globally, particularly
among those infected with HIV (≥ 40 compared to 16 per 100,000 population)
[20]. The TB situation in East and West Africa is similar with TB incidence
largely between 125-299 per 100,000 population and TB mortality between 10-20
per 100,000 population [20].
Figure 2: Graphic of the estimated global TB incidence in 2013 [20]
51.5 ECONOMIC BURDEN OF HIV-ASSOCIATED TB
Globally, over 130 million years of healthy life (DALYs) are lost due to illness
and premature mortality from TB (43,650,000) and from HIV (91,907,000)
annually [28]. Furthermore, the two diseases account for five percent of all the
DALYs world-wide each year. But the DALYs due to TB and HIV are over four
times in sub-Saharan Africa compared to the global average (8800 versus 1900
per 100,000) [29, 30]. This is because more young adults from the region die from
TB or other HIV related causes than elsewhere.
For TB, these DALYS were estimated to result in economic losses equivalent to
3.4 trillion dollars (US $) between 2006 and 2015 globally if its control was not
improved [31]. For sub-Saharan Africa, the economic losses during this ten year
period were estimated to be 519 billion dollars (US $). Furthermore, eighty
percent of these economic losses in sub-Sahara Africa were attributed to co-
infection with HIV [31].
Studies that have investigated the economic burden of TB, in patients from sub-
Sahara Africa or from low-and middle-income countries found the costs of TB
care corresponded to 35-58% of annual household income [32, 33]. Thus, for
many households, TB care costs were catastrophic and in some situations, patients
took loans or sold their household items to meet these costs. Costs of medicines,
diagnostic tests and hospitalization were important drivers of the care costs and
accounted for 20% or more of the total medical costs in many cases [32]. The
largest costs however, were due to lost income (60%) which was incurred mainly
before diagnosis and initiation of TB treatment [32]. In other situations, up-to
78% of the costs of TB care were due to direct non-medical costs such as
transport and provision of special foods as part of therapy for the TB patients
[34].
These huge economic losses at global and household level provided additional
context for the preparation of the ‘Global plan to Stop TB, 2006-2015’. Moreover,
the benefits of TB control were shown to exceed the costs of implementing the
plan in all twenty-two high-burden TB countries. In sub-Sahara Africa, the
benefits of implementing the plan exceeded the costs by roughly ten: one [19, 31].
1.6 EPIDEMIOLOGY OF HIV ASSOCIATED TB
Worldwide, an estimated 35 million people are infected with HIV [35]. As is the
case for TB, HIV infection is most common in young adults aged 15-49 years.
Since 2010 however, the number of new HIV infections has continued to decline
by 13% [35]. In addition, since 2005, AIDS related deaths have fallen by 35%
6after the global scale-up of HIV antiretroviral treatment (ART) through various
global initiatives such as the ‘3 by 5 initiative’ and PEPFAR [36, 37].
Just 15 countries account for 75% of the global HIV burden. Except for five of
them (Brazil 2%; China 2%; India 6%; Russia 2%, United States 4%), the rest are
from sub-Saharan Africa-making the region account for 70% (25 out of 35
million) of the global HIV burden [35]. Within sub-Sahara Africa, ten countries
(Ethiopia, Kenya, Malawi, Mozambique, Nigeria, South Africa, Uganda,
Tanzania, Zambia and Zimbabwe) account for 80% of all people living with HIV
with slightly more women (58%) than men having the HIV infection [35].
Not surprising therefore, 80% of the 1.1 million TB patients co-infected with HIV
globally, are from sub-Sahara Africa [20]. On average, 40% of TB patients in sub-
Sahara Africa are co-infected with HIV, with the levels of TB-HIV co-infection
highest in Southern Africa (68%) compared to Eastern (40%) and Western Africa
(25%).
The epidemiology of HIV-associated TB has therefore remained un-changed
since its earlier descriptions [38, 39]. Even in the era of ART, TB remains the
main cause of mortality among HIV patients in sub-Saharan Africa [40-42]. ART
however, reduces the risk of TB by 66% and the risk of death by 50% in people
living with HIV [43, 44]. Thus, since 2013, the WHO recommends initiation of
ART in HIV patients with CD4 count of 500 compared to CD4 count of 350
previously [45].
The risk of TB starts to increase soon after infection with HIV. The risk of TB
doubles within one year and is sustained or increased during the following years
[46]. In addition, HIV increases the risk of progression of latent TB to active TB
while on the other hand, TB increases progress of HIV infection to AIDS [47, 48].
The rapid progression to AIDS explains why there are more deaths among TB
patients co-infected with HIV during TB treatment compared to TB patients who
are not infected HIV. At a global level, the proportion of TB patients who died in
2013 during TB treatment was more than three times higher among HIV-positive
TB patients than in those who were HIV-negative (11% versus 3.4%) [20]. In
sub-Saharan Africa, HIV-positive TB patients were twice more likely to die
during TB treatment compared to HIV-negative TB patients (10% versus 5%)
[20].
The poor treatment outcomes for TB in HIV-positive patients compared to those
who are HIV negative is also related with the difficulty of diagnosis and the
treatment delays that are associated with smear-negative TB [49-52]. Smear-
negative TB is a common clinical problem in HIV patients and was described
several years before. In one review, researchers described the dis-proportionate
increase in smear-negative TB with the advent of the HIV epidemic and the
higher mortality among this group compared to smear-positive patients [53]. A
7subsequent review proposed the use of clinical algorithms for diagnosis of smear-
negative TB since additional tests to TB microscopy were generally unavailable
or inaccessible [54]. This was followed by a third review which proposed the
urgent need to change the existing policies for the diagnosis of smear-negative TB
in HIV patients from resource limited settings [55].
1.7 PATHOGENESIS OF HIV ASSOCIATED SMEAR-NEGATIVE PTB
TB is caused by the bacterium Mycobacterium tuberculosis-which is spread from
person to person through the air. Pulmonary TB is therefore the most common
form of the disease. It is also the most important for transmission control using
the strategy of early diagnosis and treatment. Diagnosis of pulmonary TB is
mainly achieved by examination of sputum examination as cough is the
commonest sign/symptom [56]. TB microscopy is the most common method for
sputum examination. However, HIV reduces the sensitivity of TB microscopy
[53-55]. How this occurs is briefly described below:
In the normal host, on inhalation of the TB bacilli, they are engulfed and
immediately killed by alveolar macrophages. This is achieved using different
bactericidal mechanisms such as reactive nitrogen and oxygen intermediates [57].
However, the bacilli may survive in 25-50% of the infected individuals and
continue to divide within macrophage cytoplasm [58]. The macrophages then
present the Mycobacterial antigen to CD4+ lymphocytes, which become activated
and initiate a cell-mediated response. The sensitized lymphocytes produce various
cytokines such as TNF-α, IFN-γ, IL-6 and IL-12 which attract and activate more
macrophages, enhancing their ability to kill the Mycobacteria [58]. Such activated
macrophages become enlarged and differentiate into what are known as epitheliod
macrophages to form a granuloma. The granuloma is a compact aggregate of
epitheliod cells populated with many other cell types such as neutrophils,
dendritic cells, natural killer cells and fibroblasts [59]. It is generally believed that
the main purpose of the granuloma is to ‘wall off’ the bacteria in the host
resulting in containment or cure in 90% of individuals [57, 58]. This view has
recently been revisited however, and the granuloma is now thought to have a role
in the dissemination of TB infection [59]
Considering that the granuloma is mainly a protective structure in the host, and
that the CD4+ lymphocyte plays an important role in the formation of the
granuloma, HIV has a detrimental effect on the formation of the granuloma by
depletion of host CD4+ lymphocytes [60, 61]. This results in poor containment of
the TB bacilli resulting in uncontrolled spread of the TB bacilli in the lung and
elsewhere in the body. In addition, the poorly formed granuloma results into less
cavitatory disease in the lungs. This results in less numbers of bacilli in the
expectorated sputum than would normally be the case in the normal host. These
numbers are often below the detection limit of microscopy (5000-10,000 bacilli
8per ml) which results in smear-negative TB [62-64]. The situation is made worse
by the weak respiratory effort in patients with advanced HIV disease resulting in
sputum of poor quality with subsequent smear-negative results [65, 66].
92 OVERVIEW OF TRADITIONAL TB DIAGNOSTICS
2.1 MICROSCOPY
Microscopy is the main method for the laboratory diagnosis of pulmonary
tuberculosis (PTB) for more than 100 years. This is achieved by direct microscopic
examination for tubercle bacilli in sputum specimens stained using the Ziehl-Neelsen
(ZN) procedure [67]. Sputum examination by microscopy is simple, inexpensive and
efficient in detecting those cases of pulmonary tuberculosis that are most infectious
[68]. Smear microscopy is also used to monitor treatment of patients and to establish
cure. However, between 5,000-10,000 bacilli/ml of sputum are required for direct
microscopy to be positive. But only a proportion of tuberculosis patients harbour such
large enough numbers of organisms to be detected in this way [69]. Thus, the
sensitivity of microscopy may be as low as 20% especially in HIV patients who have
pauci-bacillary forms of TB [70]. In addition, it is virtually impossible to distinguish
between the MTC and NTM forms of mycobacteria using the microscopy test which
may result into incorrect treatment of NTM as MTC [53, 71]. Further, the yield of TB
microscopy is highly dependent on skills of the operating technician and on the
quality of reagents which may vary from one setting to another [69].
2.2 CHEST X-RAY
Like microscopy, chest X-ray has been used for over a century to diagnose pulmonary
TB (PTB). In the pre-HIV era, PTB typically appeared on chest X-ray as cavitation
with apical or bilateral distribution [54]. Interpretation of chest X-rays of individuals
suspected to have PTB can be difficult. It is even more difficult among patients
infected with HIV because they have atypical (pulmonary infiltrates with no cavities,
lower-lobe involvement) appearance of TB on chest X-ray [72]. Moreover, chest X-
ray can appear normal in nearly one-third of HIV-positive patients with TB as their
immunity deteriorates even further [73, 74]. Studies that have evaluated the
diagnostic value of chest X-ray in smear-negative patients found that it has low to
moderate sensitivity and specificity of 28-78%, and 59-75% respectively [75, 76].
Nonetheless, chest X-ray is useful for diagnosis of extra-pulmonary TB such as
pleural or pericardial TB and other non-tubercular chest diseases such as PCP or
Kaposi’s sarcoma, which are common among people living with HIV [77].
A correct diagnosis of PTB on chest X-ray is dependent on the reader’s expertise
because interpretation is currently not well standardized. Efforts are underway
presently to introduce standardized scoring systems for interpretation of chest X-ray
and thereby increase its sensitivity and specificity. These combine clinical and chest
X-ray appearance. The available evidence indicates that the score systems could
improve sensitivity remarkably (93-98%) although specificity could still remain low
(35-50%) [78, 79]. A major limitation of chest X-ray is that it is not widely available
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in the peripheral health facilities, and even where it is available, the quality of the X-
ray is often poor.
2.3 SOLID CULTURE
Culture is the “gold standard” for TB diagnosis. Culture requires fewer bacilli (10-
100/ml) for detection and therefore allows for detection of pauci-bacillary forms of
PTB that are associated with HIV [4]. In addition, culture allows for species
identification and drug susceptibility testing which have become important because of
the increasing cases of drug-resistant TB [20]. However, implementing TB culture
requires sophisticated infrastructure and highly skilled staff thus limiting the
technology to mainly referral or research facilities.
Until 2007, solid media (egg or agar-based) was the main type of media used for TB
culture. The advantages of egg-based media include ease and ability to be prepared
in-house, it allows for observation of colonies of mixed cultures and contaminants,
and it may be stored for several weeks [4]. Löwenstein–Jensen (L-J) medium is the
most commonly used egg-based solid medium for TB culture. L-J media containing
glycerol is used to promote growth of M. tuberculosis growth, while L-J containing
sodium pyruvate without glycerol is used to promote growth of M. bovis.
Alternatively to reduce costs, L-J media without asparagin (Ogawa media) may be
used [4]. A disadvantage of egg-based media is that when contamination does occur,
it may involve the entire slant surface causing the entire culture to become lost. In
addition, if specimens contain few bacilli it may take three to eight weeks before
cultures become positive.
Agar-based media are less likely than egg-based media to become contaminated [62].
The most common are Middlebrook 7H10 and 7H11, which can be prepared in the
laboratory using commercially available agar-powdered bases [62]. After preparation,
the media is enriched with addition of Oleic acid, Albumin, Dextrose and Catalase
(OADC). Because of the transparency of 7H10 and 7H11 plates, microcolonies of
MTB with typical cord formation can be detected and counted using a microscope as
early as one week after incubation [4]. Also, visibility of colonial morphology on agar
plates is better than on egg-containing slants, aiding the identification of
mycobacteria. A disadvantage of Middlebrook media is that the surface dries more
rapidly than egg-based media.
2.4 EMPIRIC TB DIAGNOSIS
In the absence of adequate laboratory tools for TB diagnosis, the WHO recommended a
clinical algorithm involving empiric TB diagnosis and treatment for HIV prevalent and
resource constrained settings [80]. However, the way the algorithm was implemented
was highly variable among clinicians. For example, empiric TB treatment was initiated
in some situations based on clinical suspicion for TB following negative laboratory
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investigations. In other situations, clinicians initiated empiric TB treatment exclusively
based on clinician suspicion without any laboratory investigation particularly in
seriously sick patients in peripheral health facilities. Thus, in some settings, nearly 50%
of the patients could be treated for TB without smear results [81, 82].
Empiric TB treatment was of value however, in HIV-positive patients with advanced
immunodeficiency because of the frequent occurrence of smear-negative TB in such
patients [83]. Several autopsy studies provided support for this practice since half or
more of the deaths in HIV patients were due to TB [29, 41, 84, 85] . Furthermore, a
study that recently evaluated the impact of empiric TB treatment revealed that it
averted 6-25% deaths and prevented 11-57% of incident TB cases in severely immune
suppressed HIV patients (CD4 less than 100) [86].
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3 OVERVIEW ON NEW TB DIAGNOSTICS
Since 2007, the pipeline for TB diagnostics expanded tremendously and new tests
became available [87]. Between 2007 and 2015, the WHO developed many
policies based on the new tests to improve TB diagnosis and treatment. These
policies include; use of Xpert MTB/Rif test in HIV-positive patients [88], use of
LED fluorescent microscopy as an alternative to Ziehl-Neelsen microscopy, [89],
MODS and NRA to screen for MDR-TB [90], and use of liquid medium for TB
culture and DST [91] among others [92]. An overview of these tests and
implemented in this thesis is provided below:
3.1 GENEXPERT MTB/RIF TEST
Previously, molecular diagnostics for TB were limited to research laboratories.
The introduction of the automated molecular test (Xpert MTB/Rif or GeneXpert)
was considered a “game changer” in the use of molecular TB diagnostics because
it provided a practical alternative to TB microscopy and culture [93]. While
thousands of MTB must be present in each millilitre of sputum sample for PTB to
be diagnosed using the microscope, GeneXpert can detect MTB at much lower
concentrations of about 100-200 bacilli per millilitre of sputum and is able to
distinguish between MTB and NTM with very high specificity [94, 95].
GeneXpert relies on real time polymerase chain reaction (PCR) to amplify a
portion of the Mycobacteria gene where many of the mutations for resistance to
the anti TB drug rifampicin, occur (81 base pair long rpoB hot spot region) [96].
If present, fluorescent dyed molecular probes of 16-20 base pairs long, are used
for detection of the amplified Mycobacterial DNA in the clinical sample [95]. The
steps involved to process the sample, amplification of nucleic acid and detection
of the target sequences are automated. This is achieved by the use of single-use
disposable GeneXpert cartridge that hold the PCR reagents and host the PCR
process [95].
GeneXpert simultaneously detects Mycobacterium. tuberculosis and ‘drug
resistance’ within two-three hours. Moreover, being an automated test, it does not
require highly skilled staff to operate. Thus, the WHO currently recommends
GeneXpert as the primary diagnostic test for HIV associated TB in adults or in
children suspected of having TB or individuals suspected of having multi drug-
resistant TB [97]. The test is currently implemented on a global scale. However,
concerns have been raised about the cost-effectiveness of the GeneXpert because
of its high cost but limited impact on patient morbidity and mortality [98-101]
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3.2 LED MICROSCOPY
Efforts to improve TB microscopy were warranted since the method was the most
widely used in several settings where TB was a high burden. With available evidence
that Fluorescent microscopy (FM) was 10-20% more sensitive than ZN microscopy,
diagnosis of TB could be improved with deployment of FM [102]. The most important
advantage of ﬂuorescent microscopy is that it uses a lower power objective lens
(typically 25×) than traditional microscopy (typically 100×), enabling the
microscopist to assess the same area of a slide in less time [103]. Other advantages
include the simplicity of the ﬂuorochrome staining method compared with Ziehl-
Neelsen methods.
Fluorescent microscopy (FM), uses ﬂuorochrome dyes such as auramine O or
auramine-rhodamine with an intense light source. Previously, halogen or high-
pressure mercury vapour lamps were used as the light sources. In comparison,
traditional Ziehl-Neelsen microscopy could be performed using a conventional
artiﬁcial light source or reﬂected sunlight [62]. Thus, wide spread implementation of
FM was originally limited because of cost, the technical complexities of operating FM
due to need for mercury vapour light sources, the need for regular maintenance and the
requirement for a dark room.
The development of Light-emitting diodes (LED) as a source of the intense light
required for fluorescent microscopy, offered the benefits of fluorescence microscopy
without the associated previous costs. And following assessment of LED fluorescent
microscopy with evidence that it was more sensitive than the traditional Ziehl-
Neelsen microscopy and had qualitative and operational advantages, the WHO
recommended that LED fluorescence microscopy be phased in as an alternative to
Ziehl-Neelsen microscopy [89].
3.3 COMMERCIAL LIQUID CULTURE
Liquid culture is available on commercial or non-commercial basis. The use of liquid
media for TB culture allows for increased detection of MTB of about 10% in 7-14 days
compared to 21-42 days on solid media [62]. However, liquid culture is more prone to
contamination compared to solid culture. And just like solid culture, liquid culture also
requires high biosafety levels (biosafety level 3); highly skilled staff and costly
maintenance of the infrastructure and equipment.
One of the most widely used commercial liquid culture tests is the BACTEC
Mycobacteria Growth Indicator Tube System (MGIT 960). MGIT was developed as
an alternative to the radiometric BACTEC 460 TB system [104]. MGIT is fully
automated and continuously monitors growth of MTB in the culture. The system’s
culture tubes consist of modified Middlebrook 7H9 broth, growth supplement
(OADC), and a mixture of antibiotics to prevent contamination of the media. MTB
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growth is detected by the rate of oxygen consumption within the headspace of the
cultures [105]
3.4 MODS AND NRA TB CULTURE
The Microscopic-observation drug-susceptibility test (MODS) [106], and the Nitrate
Reductase Assay (NRA) [107], are common non-commercial liquid culture methods,
used mainly to screen for multi drug-resistant TB [90]. The MODS relies on two well-
known properties of Mycobacterium tuberculosis (MTB): First, the rate of growth of
MTB in liquid medium is considerably higher than that on solid medium. Second, the
morphology of MTB in liquid culture is characteristic and recognizable, consisting of so
called “cord” like structures. Based on these two characteristics, MTB growth can be
detected within 7-10 days using a microscope compared to conventional solid culture
that takes 3-8 weeks [108, 109].
The NRA assay relies on the ability of MTB to reduce nitrate to nitrite. The presence of
nitrite, indicating metabolically active mycobacteria, can easily be detected by addition
of what is known as the ‘Griess reagent’ into the culture tube to produce a pink-purple
colour change [4, 106]. By using liquid culture media for the NRA test, MTB growth can
be detected within 10-14 days which is considerably quicker than that on solid medium
[110].
Compared to the NRA, the MODS been developed further and used more extensively
including different HIV care settings [111-113]. A ‘MODS test kitTM’ has now been
developed to address the difficulties faced by many laboratories in low- and middle-
income countries to procure the consumables required for the test [114].
3.5 TB DIAGNOSTICS POST 2015
The landscape of TB diagnostics post 2015 will be different from the current one,
with less reliance on TB microscopy and conventional TB culture in the near future
[115]. Molecular based diagnostics will be expanded the most, with possible
deployment of simple molecular tests at the point of care, and use of more complex
molecular tests in specialised TB laboratories [116].
In the case of antigen and antibody tests for detection of TB, only one antigen test is
currently on the pathway to WHO evaluation [116]. The test known as TB-LAM, is
based on detection of a lipopolysaccharide called lipoarabinomannan, which is a
major cell-wall component of Mycobacterium tuberculosis [117]. TB-LAM is a
simple, cheap and rapid test with possibility for use as a point of care test. TB-LAM
was evaluated in several studies and found useful in HIV patients with severe
immune-suppression and with the highest risk of mortality if not treated [118-122].
For antibody tests, over fifty distinct antigens have been identified so far, with
potential for inclusion in an antibody-based TB test [123]. Combinations of selected
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antigens (mainly proteins) were found to have higher sensitivities than single
antigens. Currently, there are several commercial antibody TB tests mainly based
on detection of IgG or IgA antibodies. But they have inconsistent and imprecise
estimates of sensitivity and specificity and the WHO does not therefore, currently
recommend their use for TB diagnosis [124, 125].
3.6 IMPACT OF NEW TESTS ON GLOBAL TB BURDEN
Implementation of the existing new diagnostics for TB will reduce the current
burden of TB only moderately (36%). This is because the tests have difficulty in
diagnosis of TB in children and extra-pulmonary TB, coupled with other factors
such as ineffective TB treatment [126]. As a result, the current global decline in
TB incidence is only about two percent annually which is too small to end the
global TB epidemic (Figure 2).
The limited impact of the new TB diagnostics at population level has recently
been described in some studies [127-129]. A combination of new tools, which are
able to diagnose childhood TB and extra-pulmonary TB or prevent TB altogether
is therefore highly desired [130].
In 2014, the WHO developed a new post-2015 TB strategy with a goal of ending
the global TB epidemic by 2035 [131]. The strategy requires acceleration in the
decline of the incidence of TB from two percent currently to ten percent during
the next decade. To achieve this, there is need to optimally use the currently
available tests and introduction of new TB medicines and a vaccine by 2025
(Figure 3).
Figure 3: Graphic of the global targets for TB control by 2035 [131]
16
The status of these additional new technologies is as follows: According to the
pipeline report for 2014, the TB drug pipeline currently features six compounds
from four different classes [132]. Of them, only bedaquiline and pretomanid are
likely to be used for a new TB regimen for treatment of drug- sensitive and drug-
resistant TB by 2020. In the case of vaccines, the pipeline currently features 16
candidate TB vaccines which have undergone or are currently in various phases of
clinical development [132]. These fall under three categories (i) Prime vaccines
for replacement of the existing BCG vaccine using either live recombinant BCG
(rBCG) or recombinant attenuated MTB, (ii) Prime-boost vaccines for
administration as a booster in recently or remotely BCG primed individuals, and
(iii) immunotherapeutic vaccines for use as an adjunct to chemotherapy to shorten
TB treatment [133, 134]. Unfortunately, trials involving the new vaccines have so
far been disappointing revealing there are still significant gaps in understanding
the pathogenesis and immunology of tuberculosis [134, 135]
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4 THE NATIONAL HEALTH SYSTEM OF UGANDA
The National Health System (NHS) of Uganda is made up of both the public and
private health sector with each of them contributing about 50% of the reported
outputs for health services [136]. The public health sector comprising Government
of Uganda owned health facilities is structured into: National Referral Hospitals
(NRHs); Regional Referral Hospitals (RRHs) and the District Health System
(General hospitals, Health Centres 1-IV and Village Health Teams) [137]. The
District Health System is further divided into Health Sub-Districts with either a
Health Centre IV or General hospital functioning as the referral facility within the
Health Sub-District (Figure 4). The private health sector consists of Private Not for
Profit (PNFPs) providers, Private for Profit Health Practitioners (PFPs) and the
Traditional and Complementary Medicine Practitioners (TCMPs). The PFP sector
is concentrated in urban areas. The Government of Uganda (GoU) subsidizes the
PNFP and a few private hospitals as part of a Public Private Partnership strategy for
health services delivery. The subsidies cover the minimum package of health
services that was developed by the GoU for all levels of health care for both the
private and public sector. Currently, 72% of the households in Uganda live within
five kilometres from a health facility [137].
A major challenge for delivery of health services in Uganda is the low staffing
levels in health facilities. In 2011/12, the staffing level in the facilities was only
58% despite increased recruitment efforts by Government. In the rural setting,
health services are largely provided by nursing staff because of shortage of doctors
who prefer to work in urban settings [138]. In the case of the National TB and
Leprosy Programme (NTLP), the staffing level stands at 43% which is lower than
the national average. This severely constrains delivery of TB services particularly
for laboratory services [139], despite being integrated within the general health
services in the different tiers of the National Health System.
The TB laboratory network in the country comprises the National TB Reference
Laboratory (NTRL) which is responsible for all the TB laboratories in the national,
regional and district health structure. The NTRL mainly provides research and
quality assurance services while the laboratories in the health facilities perform the
direct diagnostic services for patient care. By the end of 2013, TB Culture and Drug
Susceptibility Testing (DST) services were limited to only the NTRL and three
other laboratories used for research. Accessibility to TB culture services was
therefore limited for the general population. On the other hand, TB microscopy
services based mainly on the Ziehl Neelsen procedure, were widely available up-to
the Health Centre III level. Since 2010, LED Fluorescent microscopy (FM) has
been scaled up to replace ZN in all National and Regional hospitals and some
district hospitals. LED microscopy however, still represents just 5% of the TB
microscopy network in the country.
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Figure 4: Graphic of the National Health System of Uganda. Adapted from ref [140]
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5 STUDY RATIONALE
The purpose of this study was to evaluate new tests for early and increased
diagnosis of pulmonary tuberculosis in smear-negative HIV-positive patients in
Uganda.
Uganda has an estimated population of 35 million people [141]. Communicable
diseases contribute over 50% of the disease burden in the country with malaria,
HIV-associated illness and TB as the leading cause of ill health [142]. While the
population HIV and TB prevalence have declined since the 1990s, the country
remains a high HIV burden and high TB burden country. The current HIV
prevalence for the general population is estimated at 7.3% while the TB prevalence
is estimated at 154 per 100,000 population [143, 144].
From the economic viewpoint, TB and HIV account for 22% (6,935,000 of
31,400,000) of all the DALYs due to disease and injury in Uganda annually. This
increases to 41% (16999000 of 31,400,000) considering DALYs due to infectious
diseases and parasitic infections [30]. Thus, without improved TB control, it was
estimated that Uganda would lose nearly 9 billion dollars (US $) between 2006 and
2015 [31].
Nearly 50% of the notified TB patients are co-infected with HIV, with the mortality
rate among the TB-HIV co-infected patients twice that in TB patients without HIV
infection [144]. Until 2010, only about 50% of the estimated incident TB patients
(166 per 100,000 population) were detected each year. This increased to nearly
70% in 2013 because of implementation of the WHO intensified TB case finding
policy [145]. However, a substantial proportion (30%) of the notified TB patients
each year are smear-negative and are therefore treated for TB on empirical grounds
[144].
Microscopy remains the main method for TB diagnosis in Uganda since it is the
most accessible. Unfortunately TB microscopy has a sensitivity of only 40–60%
under field conditions, falling as low as 20% in the presence of HIV co-infection
[70]. To improve the diagnosis and treatment of smear-negative TB, Uganda
adopted the WHO 2007 TB algorithm for management of smear-negative PTB in
HIV prevalent settings [80]. The algorithm begins with TB microscopy and, if
negative, followed by chest X-ray or culture. However, implementation of the
algorithm was problematic: (1) There were inadequate medical workers to
implement the algorithm fully, (2) the algorithm outlined a lengthy diagnostic
pathway that required the patient to visit the clinic four times resulting in high
dropout rates of patients during the diagnostic process, (3) access to quality chest
X-ray was limited in many of the health facilities in the periphery, (4) TB culture
was only undertaken at central level laboratories and results were seldom available
in a clinically relevant timeframe. TB diagnosis among smear-negative HIV
patients was therefore often delayed, which resulted in high mortality rates.
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With the advent of new TB diagnostics from 2007, such as liquid culture and
molecular tests, there were proposals to incorporate the new tests into the existing
WHO 2007 algorithm to improve TB diagnosis and treatment, particularly for HIV-
positive patients who were smear negative. However, the diagnostic accuracy, cost-
effectiveness and impact on patient care of these tests in Uganda was not yet
evaluated.
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6 GENERAL OBJECTIVE
The over-all aim of this thesis was to increase knowledge of using new tests on the
diagnostic accuracy, cost-effectiveness and effect on treatment of TB in smear-negative
HIV-positive patients in Uganda..
6.1 RESEARCH OBJECTIVES
 To determine and compare the over-all accuracy of the existing (WHO 2007
TB algorithm) and new (GeneXpert, MODS, NRA) tests for diagnosis of
smear-negative TB.
 To determine and compare the accuracy of GeneXpert, MODS and NRA for
diagnosis of smear-negative TB in HIV patients.
 To determine the cost-effectiveness of using MODS versus GeneXpert for
diagnosis of TB in HIV patients.
 To describe the effect of using GeneXpert on treatment of smear-negative
HIV patients.
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7 METHODS
7.1 STUDY AREA AND POPULATION
Study I involved secondary data analysis obtained from publications on the accuracy of
the existing and new TB tests for diagnosis of smear-negative TB. Study II, III and IV
were conducted at Mulago National Referral Hospital and Complex in Kampala,
Uganda. Participants were enrolled from in-patients admitted to the medical department
of the hospital, Figure 5, and out-patients attending the Mulago-Immune Suppression
Syndrome (Mulago-ISS) clinic, Figure 6.
The Mulago-ISS clinic is a doctor led out-patient HIV care facility supported by the
Makerere University Joint AIDS Program (MJAP). MJAP was funded by the U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR) since 2004 to provide free
comprehensive HIV care services including TB treatment to adults and children. MJAP
pioneered TB/HIV integrated care in Uganda, at Mulago in 2006. The TB/HIV
integrated care services include routine screening for TB symptoms among HIV
patients, implementation of routine TB infection control interventions and early
initiation of anti-retroviral-therapy (ART) for all HIV infected who are patients co-
infected with TB. As of March 2012, there were 14,000 patients receiving HIV care at
the Mulago-ISS clinic.
The laboratory tests in study II, III and IV were conducted at the Mycobacteriology
laboratory of the Department of Medical Microbiology, in the College of Health
Sciences, Makerere University, located within Mulago Hospital Complex. The
department has an established training program for graduate students pursuing research
in TB. The laboratory previously supported the training of two doctorate students in
basic TB research.
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Figure 5: Mulago National Referral Hospital, in-patients department
Figure 6: Mulago-MJAP TB-HIV out-patients clinic
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7.2 MAIN RESEARCH METHODS
Several study designs were used to approach the research objectives and are
represented in the figure 7 below. We used structured questionnaires to collect the
data for all the studies.
7.3 What is the over-all accuracy of
the existing and new TB tests for
smear-negative TB?
What is the accuracy of the new
TB tests for smear-negative TB
in HIV patients in?
What is the effect of using the
new TB tests on treatment of
smear-negative HIV patients?
What is the cost-effectiveness of
using new TB tests for diagnosis
of TB in HIV patients?
Paper
Meta-analysis
Cross-sectional
Prospective-cohort
Decision-analysis
4,571 patients
430 patients
162 patients
10,000 patients
Study designsResearch questions Sample size
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Figure 7: Overview of the study designs used in the thesis
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DATA COLLECTION METHODS
7.3.1 Study I
A systematic review followed by meta-analysis that involved 4,571 patients was
performed to summarize the over-all accuracy of two new methods (Xpert
MTB/Rif and MODS) and the existing method (WHO 2007 TB algorithm), for
diagnosis of smear-negative pulmonary tuberculosis: We searched for publications
in English without year restriction in Pubmed using the following search terms:
‘GeneXpert’, ‘Microscopic observation drug susceptibility’, and ‘WHO TB
algorithm’. We reviewed the obtained abstracts and retrieved publications for full
review based on whether the research was a diagnostic accuracy study or not. After
reading the selected publications, we reviewed their references for additional
publications. We then searched Google scholar to assess if relevant publications
were missed.  Studies were eligible if they used TB culture as the reference method
and reported data to allow for first hand computation of sensitivity and specificity
for detection of smear-negative PTB. In papers where this was not reported, we
contacted the corresponding authors to provide the required data. For each study,
data was independently extracted by one author using a standardized form and
verified by a second author. The quality of studies was assessed using a standard
tool-QUADAS [146].
7.3.2 Study II
We enrolled 430 consecutively presenting HIV patients into a cross-sectional study,
to determine the diagnostic accuracy of Xpert MTB/Rif, MODS and NRA for
smear-negative TB. We used a combination of solid and liquid TB culture as the
reference test. Patients were eligible if they had a cough for two weeks or more,
with or without fever, night sweats, loss of weight, or blood-stained sputum.
Consenting patients provided a spot and morning sputum sample, which were
examined using LED fluorescent microscopy (FM). Samples that were FM negative
were then examined further using the Xpert MTB/Rif, MODS, NRA and combined
solid/liquid TB culture
7.3.3 Study III
We used a decision analysis model to compare the cost-effectiveness of an
algorithm using MODS or Xpert for diagnosis of PTB in HIV patients from the
provider’s perspective in Uganda. The model involved a hypothetical cohort of
10,000 HIV patients with a PTB prevalence of 20%.  Cost data included equipment,
overhead, staff, space, reagents, training and quality control. The estimates for
diagnostic accuracy of the two tests were obtained from systematic reviews.
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7.3.4 Study IV
We performed a prospective cohort study with six months follow-up involving 162
smear and Xpert negative HIV patients with presumptive PTB. Patients were
evaluated for extra-PTB or other respiratory diseases using available diagnostic
tools in the hospital. Where no alternative diagnosis was made, patients were
treated with broad spectrum antibiotics or got empiric TB treatment and then
followed up for six months to assess response to treatment. The outcomes of
interest at the end of the follow-up period were cure or lost-to-follow-up or dead.
7.4 DATA ANALYSIS
7.4.1 Study I
True positive, true negative, false positive and false negative values for each study
were compiled in Microsoft Office Excel 2007 initially. The data were then entered
and analysed using Meta-disc software version 4 [147], to obtain pooled sensitivity
and specificity values of the GeneXpert, MODS and the WHO 2007 algorithm. The
pooled estimates for sensitivity and specificity of the three test methods were
presented graphically as Forrest plots. We also generated summary Receiver
Operating Characteristic (sROC) curves for each test and computed the Spearman
correlation coefficient between sensitivity and specificity to explore for
heterogeneity in the studies.
7.4.2 Study II
The laboratory results were compiled in Microsoft Access 2003. SPSS version 17
was used to analyse the compiled data to obtain the sensitivity, specificity, positive
and negative predictive values and the 95% confidence limits for each test. A
combination of solid (L-J) and liquid (MGIT) TB culture was used as the reference
test.
7.4.3 Study III
Cost data was compiled and analysed in Microsoft Office Excel 2007. Capital
equipment was annualized at a discount rate of 3% using standard tables. Cost-
effectiveness analysis was performed by in-putting the diagnostic accuracy
probabilities and the calculated unit costs into TreeAge software version 3.5. A base-
case analysis was performed using the pooled estimates for diagnostic accuracy, unit
cost and TB prevalence. Sensitivity analysis was performed using the upper and lower
limits of the three parameters in the model.
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7.4.4 Study IV
The obtained data was compiled in Microsoft Office Access 2007. Analysis was
performed using Stata version 11. Numerical data was summarized using the mean
or median. Categorical data was summarized using frequencies or proportions.
Normally distributed numerical data was compared using the T-test and non-
normally distributed numerical data was compared using the Mann–Whitney rank-
sum test. The Chi-square or Fisher’s exact tests were used to compare categorical
data. The odds of response to antibiotics were compared to the odds of no-response
to the antibiotics to obtain crude odds ratios for each patient characteristic.
Multivariate logistic regression using the crude odds ratios was performed to obtain
adjusted odds ratios. We selected patient characteristics with p-values of less than
0.2 or those with a biological plausibility to influence response to antibiotic
treatment.
7.5 ETHICAL CONSIDERATIONS
We obtained ethical permission for the research studies from the Uganda National
Council for Science and Technology (permit no: HS 1214). The main ethical concerns
involved study II and IV because they required direct interaction with individual
patients and access to their private medical information. We therefore enrolled
participants into these two studies after they provided informed consent. Another
ethical issue in these two studies was the psychological harm to the participants from
anxiety or sadness that could arise following a diagnosis of duo HIV and TB infection.
Participants diagnosed with TB/HIV co-infection therefore got additional supportive
counselling throughout the course of their treatment. Since studies I and III involved
secondary data analysis, they did not generate major ethical concerns.
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8 RESULTS AND FINDINGS
8.1 Study I
Overall, we obtained fifteen studies on GeneXpert involving 2046 patients, five studies
on MODS involving 1462 patients and four studies on the WHO 2007 TB algorithm
involving 1063 patients. The new tests (GeneXpert and MODS) had moderate
sensitivity and high specificity for smear-negative PTB. The existing WHO 2007 TB
algorithm equally had moderate sensitivity but moderate specificity (Table 1). There
was substantial variability in the studies, as measured by the inconsistence index (I-
square). For sensitivity, the I-square values were 71% for GeneXpert, 90% for MODS,
and 81% for the WHO 2007 algorithm. For specificity, the I-square values were 70%
for GeneXpert, 93% for MODS, and 89% for the WHO 2007 algorithm. Overall,
GeneXpert had the highest discriminating ability of true positivity from false
positivity (accuracy) as measured by the area under the receiver operating
characteristic curves (AUC) shown below in Table 1.
Table 1: Over-all accuracy measures of GeneXpert, MODS and WHO 2007 algorithm
Pooled estimate (range)
Test No. of studies sensitivity specificity AUC
GeneXpert 15 67 (62-71) 98 (97-99) 0.94
MODS 5 73 (66-79) 91 (89-93) 0.88
WHO 2007 algorithm 5 61 (55-67) 69 (66-72) 0.69
8.2 Study II
The sensitivity of GeneXpert, MODS and NRA for smear-negative PTB in the
study population was low. The sensitivity was lowest for MODS (24%), compared
with NRA (42%) or GeneXpert (49%). But all three tests had high specificity
values of 90% or above. Further, despite the low sensitivity of the tests, they all had
high negative predictive values: 96% for GeneXpert, 93% for NRA and 91% for
MODS. This was because of the lower PTB prevalence of about 11% in the study
patients compared to 20-30% we expected prior conducting the study, Table 2.
Table 2: PTB prevalence extrapolated from sensitivity and specificity values of the tests
Test No. culture positive No culture negative Total Prevalence %
GeneXpert 43 326 369 12
NRA 41 325 366 11
MODS 41 323 364 11
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8.3 Study III
The use of MODS for diagnosis of PTB in HIV patients, was more cost-effective
compared to GeneXpert (US$ 34 versus US$ 71 per TB patient diagnosed). This was
mainly because of the cheap cost of the MODS test (US$ 6.53 versus US$ 12.41).
Furthermore, although equipment and overheads were proportionally higher for MODS
than GeneXpert as expected, they accounted for just over 30% of the total cost of the
MODS test (Table 3). The threshold value for cost, where using GeneXpert would be
optimal over using MODS was US$ 5.92. This implied that in order to make the
GeneXpert economically competitive with MODS, the current concessional price of
the GeneXpert of about US $ 10, needs to be reduced further by nearly half.
Table 3: Details of the costs of MODS and GeneXpert by type of input (2014$)
Method, (% of total)
Type of cost MODS GeneXpert
-Consumables 3.84, (59) 10.37, (84)
-Equipment 1.76, (27) 1.37, (11)
-Staff (salary and training) 0.46, (07) 0.15, (01)
-Overheads (utilities and space) 0.29, (04) 0.29, (02)
-Quality control 0.18, (03) 0.23, (02)
Total (US$) 6.53 12.41
8.4 Study IV
The majority 88% (141 of 160) of the patients with smear and GeneXpert negative
results fully responded to treatment with broad-spectrum antibiotics and empiric TB
treatment was initiated in only 8% (12 of 160) of them, Table 4. The odds of
improvement on antibiotics were not significant with any of the socio-demographic
(age, gender, education level, employment status, marital status) or clinical (CD4 cell
count, ART status, duration on ART, previous TB treatment) characteristics except for
stage of HIV. The odds were lower (0.05) and statistically significant in patients with
advanced HIV disease than in patients with early HIV disease (OR 0.05; 95% CI 0.0-
0.42). This significance was still retained after multivariate adjustment (AOR; 0.038
(0.005-0.307). Of the twelve patients who got empiric TB treatment, only one was
culture positive. The rest were culture negative (eight) or culture status was
undetermined (three) because of contamination of the culture or missing result.
Table 4: High response to antibiotics treatment and low empiric TB treatment.
Response to antibiotic treatment Counts, (N=160) Percentage (%)
Full response to antibiotics 141 88
Initiated on TB treatment 12 8
Other treatment* 7 4
*(Kaposi’s sarcoma-1, Lung carcinoma-1 and COPD-5)
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9 DISCUSSION
9.1 MAIN FINDINGS
The purpose of this thesis was to increase knowledge on the diagnostic accuracy of
GeneXpert, MODS and NRA for smear-negative TB with focus on HIV-positive
patients, as well as their cost-effectiveness and effect on patient treatment.
We found that the tests had moderate sensitivity (67-73%) for smear-negative PTB
which reduced (24-49%) in HIV-positive patients. The finding of the moderate
sensitivity of GeneXpert from our meta-analysis, was similar to that by the Cochrane
group in a study conducted around the same period [148], and updated a year later
[149]. In addition, based on a sub-analysis of studies from high HIV prevalence
settings, we found that the sensitivity of GeneXpert for smear-negative PTB reduced,
contrary to what was generally believed at the time. This reduced sensitivity was
supported by our laboratory study and another study from the same study area [150].
The two studies showed that in HIV-positive patients, GeneXpert missed half of the TB
patients that were smear-negative.
There are new efforts now, to improve the sensitivity of GeneXpert for smear-negative
PTB. Three strategies have been used to achieve this: (1) detection of two additional
targets of Mycobacteria (IS6110 and IS1081), (2) using fully nested PCR to improve
the quality of the DNA products, (3) testing increased volumes of the PCR products.
Preliminary results of the new GeneXpert test indicate may have sensitivity equal to
culture [151].
Our meta-analysis also provided a global summary of the accuracy of the MODS test
for smear-negative PTB. A subsequent study one year later, got comparable results to
our study (73% versus 88%) [111]. Both studies indicated the relatively superior
sensitivity of MODS (a culture-based method) to GeneXpert (molecular-based method)
in the diagnosis of PTB among HIV infected patients. We also highlighted the variable
implementation of the WHO 2007 TB algorithm in our meta-analysis. Our findings
could be used as a baseline for evaluating future TB diagnostic algorithms after the new
tests are incorporated into the existing ones.
We were surprised by the low sensitivity of the GeneXpert, MODS and NRA tests in
our laboratory study. Moreover, the MODS had the lowest sensitivity contrary to what
we expected from our meta-analysis study. In the case of GeneXpert, there are two
views which have been provided to explain our results. The first view suggests that the
study participants had early TB disease and therefore had very low bacilli load in their
sputum. This view explains why GeneXpert-negative patients are less likely to die
during follow-up despite delay to initiate TB treatment [152]. The second view
suggests that the study patients had advanced HIV disease which resulted in low
bacilli load in their sputum not detectable by the GeneXpert [153, 154].
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As both kinds of patients would be seen during routine clinical care, the most
plausible explanation is that the minimum number of bacilli required for detection by
GeneXpert is far above that required for detection by culture (100-200 versus 10-100
bacilli per ml) [4, 95]. Furthermore, in our study, it is possible that the start bacilli load
in the patients’ samples was diluted even more by addition of sample reagent in the
ratio of 3:1. Although this was the recommendation by the manufacturer, a recent study
indicates that if the sample reagent is added in a ratio of 2:1, it improves the
sensitivity of GeneXpert [155].
The low sensitivity of MODS and NRA was likely because the two tests were
performed on samples stored in a fridge (4–8oC) typically for one week. Some loss of
viability could therefore have occurred during the storage period. Moreover, the tests
were declared negative after fourteen days initially which was short for any viable
Mycobacteria to grow to a level where they could be detected, especially when using
a microscope as is the case for the MODS test.
We found that using a MODS-based algorithm was more cost-effective compared to
using a GeneXpert-based algorithm for diagnosis of HIV-associated PTB. Given, the
emerging evidence of the limited effect of GeneXpert on the clinical outcomes of
patients [98, 100, 101], the cost effectiveness of using GeneXpert in resource limited
settings is currently questioned because of affordability and sustainability concerns. On
the other hand, the MODS test was specifically developed for resource limited settings
and has superior diagnostic accuracy to GeneXpert [111, 149]. As scale-up of
conventional culture methods have been limited by the high set-up and maintenance
costs [156], the MODS could be a suitable alternative because it is cheap. MODS offers
the opportunity to decentralize TB culture services. This could increase TB detection
and access to drug-susceptibility testing which is important for early diagnosis and
treatment of drug-resistant TB. A recent study from Peru suggests this is possible and
our cost-effectiveness study supports this move [157].
Nevertheless, cost-effectiveness analysis is only one of the considerations for decision
making to adopt a new technology or not. Other factors to take into account include
human resource and training requirements, impact of the new technology on the health
system as a whole, the infrastructure required to support the new technology, quality
assurance, procurement and maintenance issues among others [158]. One way to
improve the cost-efficient use of the GeneXpert is to deploy the test in populations
where the prevalence of TB is very high for example in prisons, or referral hospitals
instead of deployment in district level hospitals or Health Centres.
While sensitivity and specificity of a test describe how well it performs against the
gold standard (independent of prevalence of disease), the positive and negative
predictive values of a test are population specific and will depend on the prevalence
of disease within the population being tested [159, 160]. Generally, a higher
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prevalence will increase the positive predictive value of a test and decrease the
negative predictive value and vice versa.
Thus, despite the low sensitivity of GeneXpert, MODS and NRA, they had high
negative predictive values of 90% or above because of the lower than expected PTB
prevalence in the study participants. This low PTB prevalence was possibly due to the
high antiretroviral treatment (ART) coverage of 80%, in the study population. It is
established now that ART can prevent TB in HIV patients [43, 44]. Nevertheless, TB
remains the leading cause of mortality even in HIV patients on ART. Empiric TB
treatment could therefore, still be useful given the low-moderate sensitivity of the tests
among patients who are smear-negative. Moreover, there is more benefit of empiric TB
treatment if initiated early because TB incidence rates are three times higher during the
first three months of ART than three months post ART [161, 162].
Empiric TB treatment however, is poorly defined and is not standardized as shown by
our meta-analysis study. The WHO definition of empiric TB treatment refers to
initiation of treatment in peripheral health facilities exclusively based on clinical
suspicion (before TB investigations) for seriously sick patients [80, 163]. In practice,
empiric TB treatment is also initiated at referral health facilities based on clinical
suspicion of TB when there is no bacteriological confirmation (after TB investigations).
This common practice of empiric TB treatment is now feared to undermine the
potential effect of the new TB tests such as GeneXpert [164]. An important question
therefore, is what impact the new TB tests will have on patient treatment, specifically
on the practice of empiric TB treatment. This is important because over-treatment for
TB results in misuse of the few resources available to the TB programmes, overlooking
other treatable diagnoses and exposure of patients to potentially toxic medicines which
they do not require in the first place.
In our fourth study, we investigated how best to treat smear and GeneXpert negative
patients with the aim of lowering empiric TB treatment. We found that the combination
of a negative smear and GeneXpert test had a high negative predictive value for PTB in
our study population. This could be explained by the lower than expected PTB
prevalence (11%) in the study population. Although this prevalence was reported
elsewhere [165], it is lower than the commonly observed PTB prevalence (20-30%) in
HIV-prevalent settings [75, 76, 101].
In light of the low PTB prevalence in the study population, and the high negative
predictive value of a smear and GeneXpert negative result, we found that provision of
broad-spectrum antibiotics resulted in cure for the majority of patients. Less than 10%
of the patients got empiric TB treatment way below the current national levels of 30%
[144]. Trials are currently underway to address the question of empirical TB treatment
with focus on its benefit for prevention of mortality in HIV patients with advanced
disease and the clinical predictors HIV patients for empiric TB treatment [166]. Overall
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however, there are still few studies that have investigated the impact of the new TB
diagnostics on patient-important outcomes or health systems-level [158, 167].
9.2 METHODOLOGICAL ISSUES
9.2.1 Study I
The key strengths of the meta-analysis study included the use of a standard protocol for
conducting the review [168], and assessment of the quality of the studies [146]. We
also used various overlapping search strategies which enabled the retrieval of several
relevant publications. In addition, we explored for heterogeneity using several methods
such as sub-group analysis and generation of sROC curves [168, 169]. The study
however, was limited by the wide differences in the publications. This defeated the
logic of pooling results, although it was addressed by generation of the sROC curves. In
addition, we found few publications involving the MODS test and the WHO 2007 TB
algorithm. The small number of publicationstudies on MODS could explain why the
sensitivity for the test was 73% in our study compared to 88% in the later systematic
review [111]. As there has been no recent systematic review involving the WHO 2007
algorithm, an update of our study is necessary to include the recent publications on the
diagnostic accuracy of the algorithm [75, 76].
9.2.2 Study II
The main strength of our laboratory study was the enrollment of consecutively
presenting patients into the research. This reduced bias in patient selection [160]. In
addition, we used a combination of solid and liquid culture which is the
recommended gold standard for TB diagnostics [104]. However, the MODS and
NRA methods tests were performed on stored samples. This possibly decreased the
viability of the Mycobacteria resulting in low sensitivity of the tests in comparison to
the gold standard. Future studies involving freshly processed samples could be
considered.
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9.2.3 Study III
We modelled the cost-effectiveness of using a MODS-based algorithm versus a
GeneXpert-based algorithm for diagnosis of PTB. While models are useful alternatives
to costly trials, they are limited by the assumptions used to implement them [167].
Therefore, modelling studies still need to be supported by real-world data. Moreover,
such studies would provide additional information which is of more practical relevance
than models can provide [163]. These data include time from diagnosis to initiation of
treatment or the drop-out rate of patients from the diagnostic pathway.
9.2.4 Study IV
The major strength in this study was the prospective six-month follow-up of the smear-
and GeneXpert-negative patients following broad spectrum antibiotics or empiric TB
treatment. However, the study did not have an appropriate control group. As an
alternative to a randomized control study, a better design could have been to compare
the results from the prospective follow-up and results from retrospective program data,
possibly of one year. Thus, although we found only a few patients got empiric TB
treatment, it is not surprising that our results are contrary to those from the recent trials
involving Xpert [100, 101]. In these trials, empiric TB treatment was about 20% and
therefore, the overall benefit of our strategy for reducing empiric TB treatment was
possibly over-estimated.
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10 CONCLUSIONS
GeneXpert, MODS and NRA increase detection of PTB in patients with a smear-
negative outcome after examination by microscopy. However, additional investigations
are required in those who test negative because the three tests have low-moderate
sensitivity for PTB in patients with this outcome. The tests are reliable for initiation of
TB treatment because of their high specificity.
The diagnostic accuracy of GeneXpert for smear-negative PTB is superior to that for
MODS and the current WHO algorithm for TB diagnosis. Incorporation of GeneXpert
could therefore improve the diagnostic accuracy of existing algorithm.
From an economic view point, using MODS for diagnosis of PTB in HIV-positive
patients is more cost-effective than using GeneXpert. Therefore, where resources are
limited, the MODS could be used as an alternative to GeneXpert.
A Smear and GeneXpert negative test result has a high negative predictive value for
PTB in HIV patients with high ART coverage. In such patients, initial treatment with
broad spectrum antibiotics could be useful to reduce empiric TB treatment.  A trial of
antibiotic treatment could therefore, be incorporated in new GeneXpert-based
algorithms.
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11 AREAS FOR FUTURE RESEARCH
The findings from the studies in this thesis are useful to researchers involved in test
development, policy makers, and medical practitioners involved in TB care.
The currently available new tests have only low-moderate sensitivity for Smear-
negative TB. Future research is therefore required to develop tests with sensitivity
equivalent to culture. For some of the current new tests such as MODS and NRA, there
is need to research ways to reduce the training requirements for operating them and to
standardize the test procedures.
Policy makers, need to research the over-all benefit of using the new TB tests to the
health care system. In addition, policy makers need to research the best ways to scale-
up implementation of the new tests. For example, at what tier in the health system
should the new tests be deployed to achieve maximum effect for the invested resources.
More research is also required to estimate the epidemiological impact of the new tests
to support decisions for allocating resources to adopt the new tests. Furthermore, real-
world data is required to support the economic view that using MODS for diagnosis of
TB in HIV-positive patients is more cost-effective than using GeneXpert.
Clinicians will need to research which combination of the traditional and new tests
results in increased diagnosis of smear-negative TB. There is still need to research how
best to reduce the practice of empiric treatment for smear-negative TB using the new
tests.
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